medigraphic.com
ISSN 2078-7170 (Digital)

2020, Número 4

<< Anterior Siguiente >>

CorSalud 2020; 12 (4)


Consideraciones sobre el efecto cardiovascular de algunos antidiabéticos orales

García PA, Zayas GM, Gómez CD

Idioma: Español
Referencias bibliográficas: 33
Paginas: 432-438
Archivo PDF: 335.16 Kb.


RESUMEN

La diabetes mellitus tipo 2 se asocia a un elevado riesgo cardiovascular, dadas las proporciones epidémicas a las que está llegando; las guías de tratamiento ponen de relieve la necesidad de prevenir y reducir las complicaciones cardiovasculares y mejorar el control glucémico, especialmente en las etapas precoces de la enfermedad. Los fármacos que disminuyen o regulan la glucosa se han incrementado en los últimos años y, a consecuencia de ello, el tratamiento de la diabetes mellitus tipo 2 se ha vuelto cada vez más complejo y cambiante; por tanto, es importante conocer los diferentes medicamentos que existen hoy para el tratamiento de la diabetes mellitus y sus efectos, tanto positivos como negativos, a nivel cardiovascular. Las actuales recomendaciones hacen hincapié en la individualización de los objetivos glucémicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular diseases: A historical perspective. Lancet. 2014;383(9921):999-1008.

  2. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2(2):120-6.

  3. International Diabetes Federation. ATLAS de la DIABETES de la FID. 6ta Ed. Bélgica: International Diabetes Federation; 2014.

  4. Guzmán G, Gómez JE, Plaza LJ, Sánchez MC. Normoglucemiantes orales y riesgo cardiovascular. Rev Colomb Cardiol. 2018;25(5):333-9.

  5. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care. 2017;40(1):1-135.

  6. Powers AC, D´Alessio D. Páncreas endocrino y farmacoterapia de la diabetes mellitus e hipoglucemia. En: Brunton LL, Chabner BA, Knollmann BC (eds). Goodman & Gilman: Las bases farmacológicas de la terapéutica.12ª ed. México: McGraw Hill; 2012. p. 1237-75.

  7. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab.2011;13(3):221-8.

  8. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A Meta-analysis of Randomized Trials. JAMA. 2015;298(10):1180-8.

  9. Bae JC. Diabetes Drugs and Cardiovascular Safety. Endocrinol Metab (Seoul). 2016;31(2):239-44.

  10. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71.

  11. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs. pioglitazone therapy. Arch Intern Med. 2008;168(21):2368-75.

  12. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22(1):84-113.

  13. Lund SS, Tarnow L, Stehouwer CDA, Schalkwijk CG, TeerlinkT, Gram J, et al. Impact of metformin versus repaglinide on nonglycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2diabetes. Eur J Endocrinol. 2008;158(5):631-41.

  14. Cioffi G, Faggiano P, Lucci D, Maggioni AP, Manicardi V, Travaglini A, et al. Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. Diabetes Res Clin Pract. 2013;101(2):236-42.

  15. Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J. 2014;14(4):616-32.

  16. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on risk of cardiovascular events in type 2diabetes mellitus: a cohort study. Ann Intern Med. 2012;157(9):601-10.

  17. Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: Is there a major link? Diabetes Care. 2016;39(Suppl 2):S205-9.

  18. del Olmo González E, Carrillo Pérez M, Aguilera Gumpert S. Actualización del tratamiento farmacológico de la diabetes mellitus tipo 2. Inf Ter Sist Nac Salud. 2008;32(1):1-16.

  19. Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017;136(9):849-70..

  20. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247-57.

  21. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22.

  22. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes inpatients with type 2 diabetes. N Engl J Med.2016;375(19):1834-44.

  23. Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, et al. Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. Am Heart J. 2016;174:103-10.

  24. Abdul-Ghani M, Del Prato S, Chilton R, DeFronzo RA. SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG Outcome study. Diabetes Care. 2016;39(5):717-25.

  25. Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57.

  26. Nauck M. Incretin therapies: Highlighting common features anddifferences in the modes of action of glucagon-like peptide-1receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabet Obes Metab. 2016;18(3):203-16.

  27. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-42.

  28. Masmiquel L. Efectos cardiovasculares y seguridad de los fármacos hipoglucemiantes: Situación actual. Semergen. 2014;40(2):80-8.

  29. Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, et al. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care. 2013;36(11):3746-53.

  30. White WB, Bakris GL, Bergenstal RM, Cannon CHP, Cushman WC, Fleck P, et al. Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162(4):620-6.e1.

  31. Buchaca Faxas E, Rodríguez Amador L. Seguridad cardiovascular de los viejos y nuevos antihiperglucemiantes. Rev Cuban Med [Internet]. 2017 [citado 30/11/2019];56(2):119-25. Disponible en: http://scielo.sld.cu/pdf/med/v56n2/med04217.pdf

  32. ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-28.

  33. Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study. Diabetes Obes Metab. 2014;16(10):957-62.




2020     |     www.medigraphic.com